MedTrace Logo

First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension

NCT01247116 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2018-06-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the strategy of initiating double oral combination therapy with bosentan and sildenafil at the time of diagnosis of pulmonary arterial hypertension (PAH) in a preliminary way.

Conditions

  • Hypertension, Pulmonary

Sponsors & Collaborators

  • Actelion

    collaborator INDUSTRY

  • University of Calgary

    lead OTHER

Principal Investigators

  • Naushad Hirani, MD · University of Calgary

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01247116 on ClinicalTrials.gov